BPC-157 Side Effects: Incidence Rates Across Trials

Does any BPC-157 trial give a side-effect rate?

No. In its July 2026 review, FDA described the human record as five small clinical studies: conference summaries, a retrospective chart review, a single-arm pilot and a 2-person pilot [1]. A systematic review published in 2026, with searches to June 1, 2026, found 3 studies covering 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low [5].

In those reports, side effects appear mostly as statements that none occurred rather than as rates. FDA's summary of the small studies was that 'no serious adverse events were reported, but the studies were short, small, and gave limited safety information', and its overall conclusion was that there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1].

What the one placebo-controlled study reported

The only placebo-controlled study FDA described is an ulcerative colitis trial: 53 people with mild to moderate disease received a BPC-157 enema of 80 mg or placebo once daily for 2 weeks. The abstract says the drug was well tolerated with no difference in adverse events versus placebo [1].

It has no PubMed record; the only published record is a conference summary in Gastroenterology (128:A584). FDA said it carries too little detail to judge whether the drug worked, and no full paper exists [1]. The summary does not say how many events occurred or what they were.

The other enema data come from healthy volunteers given up to 2 mg/kg daily for 8 days, reported in conference summaries; headache and flatulence were the most frequent events [1].

What the small studies recorded

• Knee pain: a retrospective chart review at one Florida clinic of 17 patients, 16 of whom were reached by phone, given intra-articular BPC-157 alone (12) or with thymosin beta-4 (4). No adverse events were noted in the review. There was no control group, results were recalled by patients, and no validated outcome tools were used [2].
• Interstitial cystitis: 12 women who had not responded to pentosan polysulfate received a total of 10 mg injected around the bladder wall in a single procedure. No adverse events were reported. Single arm, no placebo, patient-rated outcomes [3].
• Intravenous: 2 adults received 10 mg on day 1 and 20 mg on day 2. No side effects were reported, and no measurable change appeared in the tested heart, liver, kidney, thyroid or glucose markers. With n=2, this cannot establish safety [4].

What FDA's adverse-event database contains

A search of FDA's adverse-event database through December 4, 2025 returned 3 reports, all involving injectable BPC-157 [1]:

• injection-site redness and swelling lasting 9 days, in a patient who also used compounded thymosin;
• shortness of breath that led to an emergency room visit, with no other detail recorded;
• widespread darkening of the skin and gums that returned when the person was exposed again to a BPC-157 plus TB-500 'research' product.

FDA said it cannot tell whether BPC-157 caused any of them, and reported the cases individually rather than as rates [1]. FDA's page on bulk substances that may raise significant safety risks when compounded, which still carries its stated concerns, says compounded BPC-157 may pose a risk of immunogenicity for certain routes of administration, and may have problems with peptide-related impurities and characterization of the active ingredient [6].

What the animal studies flagged

In 28-day intramuscular toxicity studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels [1]. Longer studies and cancer-risk studies were not available [1].

FDA also said BPC-157's molecular targets have not been identified and its mechanisms 'remain poorly understood' [1].

Which routes have any human safety data?

Human data exist for rectal enema [1], intra-articular knee injection [2], injection around the bladder wall [3] and intravenous infusion [4]. FDA found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1]. FDA also noted websites selling BPC-157 as capsules, injections, oral sprays and nasal sprays, some labeled for research purposes only; those products are not FDA-approved drugs [1].